Method of detection of carcinogenic human papillomavirus
First Claim
Patent Images
1. A method for detection of carcinogenic human papillomavirus HPV16 and HPV33 or HPV18 which comprises;
- (a) applying a polymerase chain reaction technique to a sample of human cervical tissue cells so as to amplify the amount of a selected nucleotide sequence located within the E6 region and characteristic of carcinogenic HPV16 and HPV33 or HPV18 present, comprising the steps of;
(i) heating to dissociate the DNA strands,(ii) adding oligonucleotide primers defining each end of said nucleotide sequence,(iii) cooling to allow the primers to anneal to the dissociated DNA strands,(iv) adding DNA polymerase,(v) allowing formation, at the cooled temperature, of DNA complementary to each strand of said nucleotide sequence,(vi) heating to dissociation temperature, and repeating steps (iii) to (vi), optionally omitting step (iv) where a heat stable DNA polymerase is used; and
(b) detecting the presence or absence in the amplified sample of said nucleotide sequence of HPV16 and HPV33 or HPV18 wherein the pair of primers defining the selected nucleotide sequence are;
for HPV16 and HPV33 5'"'"' TGAGGTATATGACTTTGCTTTT3'"'"' and 3'"'"' AATTAATCCACATAAT5'"'"'or for HPV18 5'"'"' ACAGTATTGGAACTTACAGA3'"'"' and 3'"'"' TTTACATATCTAAAAATAAG5'"'"'.
5 Assignments
0 Petitions
Accused Products
Abstract
Carcinogenic human papillomavirus types HPV16 and HPV18 are detected in a sample of cervical tissue. A selected characteristic DNA portion of the virus defined by oligonucleotide primers is amplified using a polymerase chain reaction involving successive heating and cooling steps, for example up to 250,000 copies. The presence/absence of the characteristic cloned DNA portion is detected by gel electrophoresis or using a labelled oligonucleotide probe.
51 Citations
12 Claims
-
1. A method for detection of carcinogenic human papillomavirus HPV16 and HPV33 or HPV18 which comprises;
-
(a) applying a polymerase chain reaction technique to a sample of human cervical tissue cells so as to amplify the amount of a selected nucleotide sequence located within the E6 region and characteristic of carcinogenic HPV16 and HPV33 or HPV18 present, comprising the steps of; (i) heating to dissociate the DNA strands, (ii) adding oligonucleotide primers defining each end of said nucleotide sequence, (iii) cooling to allow the primers to anneal to the dissociated DNA strands, (iv) adding DNA polymerase, (v) allowing formation, at the cooled temperature, of DNA complementary to each strand of said nucleotide sequence, (vi) heating to dissociation temperature, and repeating steps (iii) to (vi), optionally omitting step (iv) where a heat stable DNA polymerase is used; and (b) detecting the presence or absence in the amplified sample of said nucleotide sequence of HPV16 and HPV33 or HPV18 wherein the pair of primers defining the selected nucleotide sequence are; for HPV16 and HPV33 5'"'"' TGAGGTATATGACTTTGCTTTT3'"'"' and 3'"'"' AATTAATCCACATAAT5'"'"' or for HPV18 5'"'"' ACAGTATTGGAACTTACAGA3'"'"' and 3'"'"' TTTACATATCTAAAAATAAG5'"'"'. - View Dependent Claims (2, 3, 4, 5, 6, 7, 10, 11, 12)
-
-
8. A primer composition which consists of:
-
(i) for HPV16 and HPV33 a mixture of 5'"'"' TGAGGTATATGACTTTGCTTTT3'"'"' AND 3'"'"' AATTAATCCACATAAT5'"'"' or (ii) for HPV 18 a mixture of 5'"'"' ACAGTATTGGAACTTACAGA3'"'"' and 3'"'"' TTTACATATCTAAAAATAAG5'"'"'.
-
-
9. A labelled oligonucleotide probe wherein the oligonucleotide is
(i) for HPV16 GTGAGTATAGACATTAT or (ii) for HPV18 GATTTATTTGTGGTGTATAGA.
Specification